Article Navigation
Article Contents
-
Abstract
Journal Article Accepted manuscript
, Jimmy Faivre, PhD Search for other works by this author on: Oxford Academic Kevin Wu, PharmD Revance Therapeutics, Inc. , Nashville, TN , USA Search for other works by this author on: Oxford Academic Mélanie Gallet, BSc R&D Technician , Teoxane SA, Geneva , Switzerland Search for other works by this author on: Oxford Academic Julia Sparrow, PhD Revance Therapeutics, Inc. , Nashville, TN , USA Search for other works by this author on: Oxford Academic François Bourdon, M Eng R&D director , Teoxane SA, Geneva , Switzerland Search for other works by this author on: Oxford Academic Conor J Gallagher, PhD Medical Affairs and Scientific Innovation, Revance Therapeutics, Inc. , Nashville, TN , USA Corresponding Author: Dr Conor J. Gallagher, Medical Affairs, Revance Therapeutics, Inc., 7555 Gateway Blvd, Newark, CA, 94560 USA, Email: cgallagher@revance.com Search for other works by this author on: Oxford Academic
Aesthetic Surgery Journal, sjae032, https://doi.org/10.1093/asj/sjae032
Published:
16 February 2024
Article history
Received:
23 December 2023
Revision received:
01 February 2024
Accepted:
05 February 2024
Published:
16 February 2024
- Split View
- Views
- Article contents
- Figures & tables
- Video
- Audio
- Supplementary Data
-
Cite
Cite
Jimmy Faivre, Kevin Wu, Mélanie Gallet, Julia Sparrow, François Bourdon, Conor J Gallagher, Comparison of Hyaluronidase-Mediated Degradation Kinetics of Commercially Available Hyaluronic Acid Fillers In Vitro, Aesthetic Surgery Journal, 2024;, sjae032, https://doi.org/10.1093/asj/sjae032
Close
Search
Close
Search
Advanced Search
Search Menu
Abstract
Background
Hyaluronic acid (HA)-based fillers are degradable with hyaluronidase, which allows for better management of adverse effects and reversal of suboptimal treatment outcomes.
Objectives
To compare the enzymatic degradation kinetics of 16 commercially available HA-based fillers, representing 6 manufacturing technologies.
Methods
In this nonclinical study, a recently developed in vitro multidose hyaluronidase administration protocol was used to induce degradation of HA-based fillers, which allowed for real-time evaluation of viscoelastic properties at near static conditions. Each filler was exposed to repeated doses of hyaluronidase at intervals of 5 minutes to reach the degradation threshold of G’ ≤ 30 Pa.
Results
Noticeable differences in degradation characteristics were observed based on the design and technology of different filler classes. Vycross fillers were the most difficult to degrade and the Cohesive Polydensified Matrix filler was the least difficult to degrade. Preserved Network Technology products demonstrated proportional increases in gel degradation time and enzyme volume required for degradation across the individual RHA products and indication categories. No obvious relationship was observed between gel degradation characteristics and the individual parameters of HA concentration, HA chain length, or the degree of modification of each filler when analyzed separately; however, a general correlation was identified with certain physicochemical properties.
Conclusions
Manufacturing technology was the most important factor influencing the reversibility of an HA product. An understanding of the differential degradation profiles of commercially available fillers will allow clinicians to select products that offer a higher margin of safety due to their preferential reversibility.
Accepted manuscripts
Accepted manuscripts are PDF versions of the author’s final manuscript, as accepted for publication by the journal but prior to copyediting or typesetting. They can be cited using the author(s), article title, journal title, year of online publication, and DOI. They will be replaced by the final typeset articles, which may therefore contain changes. The DOI will remain the same throughout.
This content is only available as a PDF.
© The Author(s) 2024. Published by Oxford University Press on behalf of The Aesthetic Society.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs licence (https://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial reproduction and distribution of the work, in any medium, provided the original work is not altered or transformed in any way, and that the work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Topic:
- rheumatoid arthritis
- gel
- hyaluronic acid
- hyaluronidase
- safety
- technology
- enzymes
- kinetics
- treatment outcome
- catabolism
Subject
Cosmetic Medicine
Issue Section:
Original Article
Download all slides
Advertisem*nt
Citations
Views
39
Altmetric
More metrics information
Metrics
Total Views 39
0 Pageviews
39 PDF Downloads
Since 2/1/2024
Month: | Total Views: |
---|---|
February 2024 | 39 |
Citations
Powered by Dimensions
Altmetrics
Email alerts
Article activity alert
Advance article alerts
New issue alert
Subject alert
Receive exclusive offers and updates from Oxford Academic
Long-term Prognosis of Vision Loss Caused by Facial Hyaluronic Acid Injections and the Potential Approaches to Address This Catastrophic Event
Efficacy of Percutaneous Superficial Temporal Arterial Hyaluronidase Injection for Hyaluronic Acid Filler–Induced Necrosis of Frontotemporal Skin and/or the Ipsilateral Scalp With Subsequent Alopecia
Efficacy of Percutaneous Intraarterial Facial/Supratrochlear Arterial Hyaluronidase Injection for Treatment of Vascular Embolism Resulting From Hyaluronic Acid Filler Cosmetic Injection
Commentary on: Efficacy of Percutaneous Intraarterial Facial/Supratrochlear Arterial Hyaluronidase Injection for Treatment of Vascular Embolism Resulting From Hyaluronic Acid Filler Cosmetic Injection
Related articles in PubMed
Citing articles via
Google Scholar
-
Latest
-
Most Read
-
Most Cited
More from Oxford Academic
Cosmetic Medicine
Medicine and Health
Plastic and Reconstructive Surgery
Surgery
Books
Journals
Halifax, Nova Scotia
Brockville, Ontario
Crows Nest, New South Wales
Omaha, Nebraska
Advertisem*nt